Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Raw Materials (2018 - 2025)

TransMedics (TMDX) has 8 years of Raw Materials data on record, last reported at $26.2 million in Q4 2025.

  • For Q4 2025, Raw Materials fell 6.34% year-over-year to $26.2 million; the TTM value through Dec 2025 reached $26.2 million, down 6.34%, while the annual FY2025 figure was $26.2 million, 6.34% down from the prior year.
  • Raw Materials reached $26.2 million in Q4 2025 per TMDX's latest filing, up from $20.3 million in the prior quarter.
  • Across five years, Raw Materials topped out at $28.0 million in Q3 2024 and bottomed at $6.1 million in Q1 2021.
  • Average Raw Materials over 5 years is $16.8 million, with a median of $17.0 million recorded in 2023.
  • Peak YoY movement for Raw Materials: skyrocketed 136.06% in 2023, then tumbled 30.35% in 2025.
  • A 5-year view of Raw Materials shows it stood at $7.3 million in 2021, then skyrocketed by 50.38% to $10.9 million in 2022, then surged by 136.06% to $25.8 million in 2023, then rose by 8.54% to $28.0 million in 2024, then decreased by 6.34% to $26.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $26.2 million in Q4 2025, $20.3 million in Q3 2025, and $19.2 million in Q2 2025.